Rein Therapeutics Inc.

US$0.61As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:RNTXHealthcare
Country USA
PE (Fwd) •••
TSR 9Y CAGR (46.74%)
Div yield —
ROE (96.42%)
Biotechnology
Beta (5Y) 1.44
PE TTM —
TSR TTM (60.79%)
Mkt cap US$52.94M
ROIC (25.14%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.655
6.76%
(86.66%)
Hold 2|7|5|8|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
4.56%
0.68%
15.65%
22.00%
Revenue$M
3.459
3.572
3.590
3.567
0.50%
4.46%
6.74%
6.67%
Peers (US$52.94M)
Cap (US$)
PE
52.40M
—
52.58M
—
Capital
TTM
5Y
10Y
Leveragex
0.760
0.205
0.183
EBIT/Intx
0.330
0.080
0.101
Own earn%
(175.58)
(69.52)
(70.37)
Sh yield%
10.28
40.66
37.47
Owners
Insiders/Inst%
13.84
41.11
Short interest%
3.63
SBC / revenue%
4.52
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
25
Op margin range%
10–17
$1 testx
—
Incr. ROIC%
4